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Abstract
Background: Management of acute respiratory distress syndrome (ARDS) in the intensive care unit (ICU) is
clinically challenging and costly. Neuromuscular blocking agents may facilitate mechanical ventilation and improve
oxygenation, but may result in prolonged recovery of neuromuscular function and acute quadriplegic myopathy
syndrome (AQMS). The goal of this study was to address a hypothetical question via computer modeling: Would
a reduction in intubation time of 6 hours and/or a reduction in the incidence of AQMS from 25% to 21%, provide
enough benefit to justify a drug with an additional expenditure of $267 (the difference in acquisition cost between
a generic and brand name neuromuscular blocker)?
Methods: The base case was a 55 year-old man in the ICU with ARDS who receives neuromuscular blockade
for 3.5 days. A Markov model was designed with hypothetical patients in 1 of 6 mutually exclusive health states:
ICU-intubated, ICU-extubated, hospital ward, long-term care, home, or death, over a period of 6 months. The
net monetary benefit was computed.
Results: Our computer simulation modeling predicted the mean cost for ARDS patients receiving standard care
for 6 months to be $62,238 (5% – 95% percentiles $42,259 – $83,766), with an overall 6-month mortality of 39%.
Assuming a ceiling ratio of $35,000, even if a drug (that cost $267 more) hypothetically reduced AQMS from 25%
to 21% and decreased intubation time by 6 hours, the net monetary benefit would only equal $137.
Conclusion:  ARDS patients receiving a neuromuscular blocker have a high mortality, and unpredictable
outcome, which results in large variability in costs per case. If a patient dies, there is no benefit to any drug that
reduces ventilation time or AQMS incidence. A prospective, randomized pharmacoeconomic study of
neuromuscular blockers in the ICU to asses AQMS or intubation times is impractical because of the highly variable
clinical course of patients with ARDS.
Background
Management of patients with acute respiratory distress
syndrome (ARDS) in the intensive care unit (ICU) is clin-
ically challenging and costly [1]. In ARDS patients with
refractory hypoxemia, neuromuscular blocking agents
may facilitate mechanical ventilation and improve oxy-
genation. However, prolonged recovery of neuromuscular
function and development of acute quadriplegic myopa-
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Table 1: Drug acquisition costs for 3.5 day cycle of neuromuscular blockade using average wholesale price (AWP)
Load 
(mg)
Mg infusion 
rate/hr
AWP vial 
($)
Vial size 
(mg)
Cost/mg 
($)
Load cost 
($)
Cycle 
infusion cost 
($)
Daily cost 
($)
Total cost 
per cycle 
($)
Total mgs Opened 
vials
Total cost 
per cycle 
with open 
vials ($)
Vecuronium 7 4 9.69 10 0.97 6.78 326 93 332 343 35 339
Cisatracurium 14 8 174.5 200 0.87 12.22 586 168 599 686 4 698
Cost difference = $ 267 $ 359
Table 2: Drug acquisition costs for 3.5 day cycle of neuromuscular blockade using average selling price
Load 
(mg)
Mg infusion 
rate/hr
Mean sales 
price ($)
Vial size 
(mg)
Cost/mg 
($)
Load cost 
($)
Cycle 
infusion cost 
($)
Daily cost 
($)
Total cost 
per cycle 
($)
Total mgs Opened 
vials
Total cost 
per cycle 
with open 
vials ($)
Vecuronium 7 4 3.58 10 0.36 2.5 120 34 123 343 35 125
Cisatracurium 14 8 119.5 200 0.60 8.4 402 115 410 686 4 478
Cost difference = $ 287 $ 353BMC Medical Informatics and Decision Making 2006, 6:15 http://www.biomedcentral.com/1472-6947/6/15
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thy syndrome (AQMS) can occur [2]. While a variety of
neuromuscular blockers have been utilized, it remains
unclear which agent provides the optimal clinical benefit
relative to the drug acquisition cost [3]. For example,
using average wholesale prices, the cost of treating an
ARDS patient with cisatracurium for 3.5 days is approxi-
mately $267 more than if the patient received vecuro-
nium. (Table 1 and 2)
Assessing the clinical and economic consequences of
pharmacological interventions in ARDS patients is diffi-
cult. The reasons include a heterogeneous patient popula-
tion, a wide range of supportive interventions, and
complex causes of the patient's condition. For example, to
conduct a clinical trial with sufficient statistical power to
detect a 10% absolute decrease in the incidence of AQMS,
a randomized clinical trial would have to enroll 800
patients in each of the two groups, assuming censoring
due to mortality is 30%. In such situations where clinical
studies are expensive and complicated to complete, com-
puter modeling is an appropriate initial approach to yield
insights.
The goal of this study was to address a hypothetical ques-
tion via computer modeling: Would a reduction in intu-
bation time of 6 hours and/or a reduction in the incidence
AQMS from 25% to 21% in ARDS patients, provide
enough benefit to justify an additional expenditure of
$267 [2,4]?
Methods
Overview of computer model
The numerator in the incremental cost-effectiveness ratio
takes into consideration the additional costs that one
intervention imposes over another. The denominator
considers the incremental improvement in health related
quality of life calculated as quality-adjusted life-years
(QALY). Both costs and QALYs need to be considered
together, otherwise death becomes the least costly option.
Using the results of our literature review, we simulated the
rates of healing and complications associated with
patients with ARDS, computed associated incremental
costs, assumed a societal perspective for the analysis as
recommended by an expert panel, estimated quality of life
for relevant health states, and performed a sensitivity
analysis to evaluate the impact of changing key variables
[5].
Markov model
Conventional models based on decision trees are limited
in their ability to describe events that can occur multiple
times in the care of a patient (e.g., ICU readmissions). A
Markov model is a mathematical representation of
patients in a series of health states. Such a model provides
a tool to deal with multiple clinical uncertainties because
the study can be repeated in successive iterations by vary-
ing parameters to address "What if?" questions. The use of
Markov models is particular relevant in the ICU settings
given the constantly changing nature of the patients' dis-
ease conditions and treatments. This methodology has
been applied successfully in studying the incidence of
nosocomial infections in critically ill patients, and the
mortality of ICU patients with sepsis [6,7].
Base case
For our study, we chose the following base case; a 55 year-
old man is admitted to the ICU because of ARDS second-
ary to pneumonia (pneumonia sepsis is the most com-
mon etiology for ARDS and receives neuromuscular
blockade for 3.5 days. These hypothetical patients were
modeled to be in 1 of 6 mutually exclusive health states:
ICU-intubated, ICU-extubated, hospital ward, long-term
care, home, or death, over a period of 6 months. (Figure
1)
A 3.5-day cycle time was chosen because it approximates
the time of important clinical changes. Six months was
chosen because it allows the model to consider the natural
progression and resolution of the disease over a reasona-
ble time frame. We also modeled a 1-month period.
Choosing a longer period such as 12 or 24 months period
would have been unnecessarily long.
Net monetary benefit
The incremental cost-effectiveness ratio has poor statisti-
cal properties within the range of values relevant to this
Markov model for patient with ARDS receiving neuromuscu- lar blockade Figure 1
Markov model for patient with ARDS receiving neu-
romuscular blockade. Simulated patients were classified 
into 6 health states. Patient progression was divided into 3.5-
day cycles over a 6-month period.
  
ICU
Intubated
Hospital 
Ward
Off-site
Long term care
Home
Death ICU
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study [8]. If two drugs provide similar effectiveness, then
trying to calculate the incremental cost-effectiveness ratio
results in division by zero. Difficulties arise in how to
place a monetary value on a clinical improvement. This
valuation is performed by assigning a monetary value to a
unit of effectiveness (Z), and multiplying it by the net
number of units of effectiveness achieved. The value Z rep-
resents the maximum amount that society would be will-
ing to pay for the incremental improvement in outcome
(and therefore its maximum value). Medical interventions
with a cost-effectiveness of less than $35,000 (Z) per
QALY are generally considered to represent acceptable
value for money, i.e., be cost-effective. As there is no cor-
rect or well-accepted value of Z for a given clinical
improvement, we tested a range of Z values from 0 to
$100,000. The net monetary benefit addresses these con-
cerns by assigning a monetary value to the incremental
benefit achieved, and subtracting from this the incremen-
tal cost of achieving this benefit [9].
A positive net monetary benefit implies that the cost of a
new therapy is less than the value of the additional benefit
achieved. A negative net monetary benefit implies that an
intervention should be rejected, as its costs are higher than
the value of the benefit achieved [10].
Hospital costs and health related quality of life
Total hospital costs can be separated into fixed (which do
not change in proportion to the number of ICU cases) and
variable components. For example, from the facility's per-
spective, nursing care time may be considered a fixed cost,
as staff is paid regardless of whether there is one more or
one less ICU patient. However, we assumed that having a
provider take care of an ARDS patient is an incremental
cost to society, as is commonly done in cost-effectiveness
studies, to reflect that, from society's point of view, there
is a cost for the provider's time and expertise.
Using data gathered from the literature and utilizing a
"bottom up" cost methodology, we estimated direct med-
ical costs per day as the hypothetical patients progressed
thru the various health states. We assumed that 10% of
the costs assigned to any of the health states are for physi-
cians' professional services [11]. We assumed that daily
costs in any of the health states are linear, meaning that
the first ICU day, for example, is equally costly as subse-
quent ICU days.
Quality-adjusted life-years include a length of time com-
ponent (e.g., one year) and a quality of life component
(i.e., utility). Health utility is the numerical valuation of
one's health-related quality of life on a linear scale from
0.00 (death) to 1.00 (perfect health). For example, one
quality-adjusted life-year for an individual in perfect
health (with a utility = 1.0) for one year (QALY = 1) is con-
sidered equivalent to two years in a health state with util-
ity = 0.5. (QALY = 1). The advantage of using QALYs is
that they combine number of years saved as well as the
quality of life of those years.
Directly ascertaining utilities in critically ill patients is
done infrequently and is methodologically difficult [12].
Published utilities from subgroups of ICU patients have
been confirmed with the EuroQol scale and the Rosser
index [13-15]. Patients in the EuroQol© EQ-5D scale are
classified into one of 243 (35) health states (mobility, self-
care, usual activity, pain, mood) [16]. Each state is scored
from 1 (normal) to 3 (the most impaired). For example, a
mobility score of "1" indicates "no problems in walking
about," while a "3" is "confined to bed." The scores for the
five states can be assigned a utility valuation from the gen-
eral public. For example, a EuroQol mobility (3), self-care
(3), usual activity (3), pain (2), mood (1) signifies a utility
of 0.08. In contrast, EuroQol mobility (1), self-care (1),
usual activity (2), pain (1), mood (2) signifies a utility of
0.65.
Table 4: Fraction of patients in each health state after 1 month 
and 6 months
Health state After 1 month After 6 months
ICU intubated 28% 6%
ICU extubated 23% 6%
Hospital ward 9% 4%
Off site long term care 9% 18%
Home 8% 28%
Dead 23% 39%
Table 3: Costs and utilities used for each health state for computer modeling
Health state Cost per day ($) Range Utility Range
Low ($) High ($)
ICU intubated 2200 140024,25 370026,27 0.1 0.08–0.15
ICU extubated 150028 70029 2400 0.2 0.1 – 0.3
Hospital ward 700 45030,31 1700 0.5 0.25–0.5632
Long term care 350 10033 925 0.65 0.4534 – 0.7735,36
Home 0 0.80 0.7837 – 0.9238,39BMC Medical Informatics and Decision Making 2006, 6:15 http://www.biomedcentral.com/1472-6947/6/15
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In the Rosser classification of illness, assigning levels of
disability and distress to each health state determine the
quality of life of a patient. For example, Rosser Disability
level VII with Distress level B (mild) indicates a utility of
0.8.
Since health values of seriously ill patients vary widely, we
incorporated a wide range of quality of life for each health
state, assuming no state was worse than death. (Table 3)
Question asked of computer modeling
The computer modeling of the natural history of ARDS
used incidences of progressing through the health states as
estimated from the articles retrieved from the literature.
We then asked the question, "Would a reduction in intu-
bation time of 6 hours and/or a reduction in the incidence
AQMS from 25% to 21% in ARDS patients, provide
enough benefit to justify an additional expenditure of
$267? Four scenarios were specifically considered (1) the
Table 6: Cohort studies of patients with ARDS published after 1999
Author Estenssoro46 Luhr47 Davidson48 Arroliga49 Reynolds50 Angus13 Fialkow51
Study type prospective prospective prospective retrospective retrospective prospective retrospective
# of subjects 235 221 127 66 720 200 30
M e a n  a g e  ( y r s ) 5 56 13 96 0 4 95 1
Severity of 
illness
21** 19** 73*** 23** 17** 18**
Pa02/FiO2 141 131 111
ICU days 
(range)
12 16 (0–93) 21
Ventilator days
Hospital days 
(range)
28(1–150) 26 (0–117) 44
3 day mortality 34%
ICU mortality 47% 47%
In-hospital 
mortality
58% 43% 36%
30 day mortality 41% 49% 30.5%
6 mth mortality 44.3%
1 yr mortality 47% 44%
* SAPS; **Apache 2; *** Apache 3
Table 5: Randomized control trials of treatments for ARDS published after 1998
Author Derdak40 Eisner41 Gattinoni42 ARDS 
network43
Ely44 Lagneau45
Subjects All comers ARDS Pneumonia ARDS All comers ARDS All comers ARDS ARDS network 
(age <70)
Pa02/FiO2 < 200
Intervention Ventilation-
controlled or high 
frequency
Tidal volume 12 
ml/kg or 6 ml/kg
Supine vs. prone Placebo vs. 
ketoconazole
Tidal volume 12 
ml/kg or 6 ml/kg
Cisatracurium 0/4 
twitches or 2/4 
twitches
# of subjects 147 320 304 234 729 102
M e a n  a g e  ( y r s ) 4 95 15 85 34 65 6
Severity of illness 22** 84*** 40* 81*** 73*** 41*
Pa02/FiO2 113 133 127 145 130
ICU days 19
Days on ventilator 21 10
In-hospital 
mortality
35% 45%
% with unassisted 
breathing at 1 mth
57% 59%
10 day mortality 25%, 21%
30 day mortality 52%, 37% 25%
6 mth mortality 59%, 47% 36% 59%, 63% 30%
Ventilator free 
days in first 28 
days
10
reintubation 7.5%BMC Medical Informatics and Decision Making 2006, 6:15 http://www.biomedcentral.com/1472-6947/6/15
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Table 7: ICU studies of mechanically ventilated patients receiving neuromuscular blockers
Newman52 Rudis53 Kupfer54 Douglass55 Prielipp4 Segredo56
Study type Prospective Prospective Prospective Retrospective Prospective Prospective
Randomized Yes Yes No No Yes No
Patients ICU ICU VEC > 6 hrs Asthma ICU VEC>24 hrs
# of subjects 61 77 10 25 54 16
Mean age(yrs) 51 54 34 39 49
Apache score 18 73 27
Neuromuscular 
blocker
CISATRA (n = 40) 
ATRA (n = 21)
VEC (n = 35 
standard 
Assessment; N= 
42 nerve stim) 65 
survivors
VEC VEC 22 of 25 pts CISTATRA (n = 
28) VEC (n = 30)
VEC
Dose (mean) CISATRA 3.1 ug/
kg/min ATRA 10.4 
ug/kg/min
VEC load 0.08 mg/
kg infusion 0.08 
mg/kg/hr dosing 
individualized
492 mg (SD692 
mg)
CISTATRA 2.6 
mg/kg/hr VEC 0.9 
mg/kg/hr twitch 
monitor
Duration of 
infusion
47 hrs Standard 
assessment- 55.1 
+/- 34.3 hrs Nerve 
stimulation 43.2 +/
- 31.8
6.6 days CISTATRA 80 +/- 
7 h VEC 66 +/- 12 
h.
Recovery from 
block
1 hour 70% TOF 
for both drugs
50% of control pts 
recovery was 3.5 
hrs (95% CI 2–8) 
vs. 1.7 hrs (95% CI 
1–2) in nerve stim 
patients
7/10 pts with 
weakness, 3/10 
muscle wasting, 2/
10 difficulty 
weaning
70% TOF ratio 
CISTATRA 68 +/- 
13 min VEC 387 +/
- 163 min, longer 
(P = 0.02)
7 of 16 pts had 
prolonged block 
(l6 hrs – 7 days)
Neuro- muscular 
Outcome
No patient 
showed evidence 
of weakness 
following 
discontinuation of 
either CISATRA 
or ATRA
Median time for 
50% of control pts 
to breathe 
spontaneously was 
4.8 hrs (95% CI 3–
9) compared with 
2 hrs (95% CI 2–5)
11 of 35 control 
pts had prolonged 
block (>4 hr) 5/42 
perip nerve stim 
pts had long block 
(p < .05)
3 survivors needed 
physical therapy 
for 35 to 137 days
Pts with 
polyneuropathy 
1352 mg in 7.2 
days
Without 
polyneuropathy 
528 mg for 3.8 
days (p0.04)
9/25 had weakness 
Patients with 
myopathy had 
significantly higher 
total dose of VEC 
(p < 0.001)
Prolonged 
recovery 
CISTATRA: 2 
patients VEC : 13 
patients P = 0.002
1 VEC patient 
significant 
myopathy
deLemos57 Khuenl-Brady58 Leatherman59 Coakley60 Murray61 Coakley62
Study Type Prospective Prospective Retrospective Prospective Prospective Prospective
R a n d o m i z e d N oN oN oN oY e sN o
Patients ICU Block > 2 days Asthma ICU >7 days ICU ICU >7 days
# of subjects 30 60 107 44 40 23
Mean age (yrs) 42 36 60 52 55
Apache 26 19 27 15.9
Neuromusc. 
blocker
PANC with TOF 
titrate
PANC (n = 30) 
PIPE (n = 30)
ATRA, PANC, 
VEC
DOX, PANC 15 of 23 received
Dose (mean) Intermittent group 
(n = 14) 0.02 mg/
kg/hr) Continuous 
Infusion (n = 16) 
.04 mg/kg/hr
3 mg/h with both DOX (0.04 mg/kg) 
PANC (0.07 mg/
kg)
Duration Of 
infusion
6 days > 48 hrs > 7 days 2.5 daysBMC Medical Informatics and Decision Making 2006, 6:15 http://www.biomedcentral.com/1472-6947/6/15
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agent reduces the incidence of myopathy from 25 to 21%,
(2) the agent reduces the duration of mechanical ventila-
tion by 6 hours, (3) both; (4) neither.
Sensitivity analyses
The probabilistic sensitivity analysis considered uncer-
tainties in all probabilities, utilities, and costs simultane-
ously. Mean values for the net monetary benefit were
calculated for results of N = 10,000 Monte-Carlo simula-
tions (@Risk 4.0, Newfield, NY, Palisade Corporation).
Triangular distributions were used for parameter values,
with the mode being the base case and the 5th and 95th
percentiles being the lower and upper limits of the ranges
reported [17].
All costs are reported in year 2004 U.S. dollars. We dis-
counted all future costs and quality-adjusted life-years at
3% per annum [18].
Results
ARDS patients receiving a neuromuscular blocker have a
high mortality, and unpredictable outcome, which results
in large variability in costs per case. If a patient dies, there
is no benefit to a drug that reduces ventilation time or
AQMS incidence.
Computer modeling
The estimated mean total cost for an ARDS patient receiv-
ing standard care for 6 months was $62,238 (5% – 95%
percentiles $42,259 – $83,766; median, $61,885). Our
computer model predicted that out of 100 hypothetical
patients with ARDS, 39% would be expected to be dead
after 6 months. (Table 4)
Results of literature review are in Tables 5, 6, 7.
Assuming society would be willing to pay $35,000 for an
additional quality adjusted life (i.e., ceiling ratio), even if
a drug (that cost $267 more) did reduce AQMS from 25%
to 21% and decrease intubation time by 6 hours, the net
monetary benefit would only equal $137. By running
repeated iterations of the model, Figure 2 has a scatter plot
of the joint distribution of the mean incremental costs
(mean decrease US $96, SD $5,134) and mean incremen-
tal QALYs (mean increase of 0.12, SD 0.0159) gained for
bootstrap samples. For the base case, the net monetary
benefit of reducing both AQMS and ventilation time
would be positive for only 51% of patients.
Sensitivity analysis
The net monetary benefit was positive for 50% of simula-
tions with a ceiling ratio of $1,000 versus 51% if the ceil-
ing ratio was increased to $100,000. The lack of sensitivity
was caused by the mean changes in QALY and cost to be
small relative to their standard deviations.
The variables that had the largest influence on the results,
from most to least important, were probability from ICU
intubated to death, probability from ICU intubated to
extubated, and probability from ICU extubated to ward.
The better the patients do overall, the larger the net mon-
etary benefit of a drug that reduces AQMS and/or intuba-
tion times.
Discussion
To properly allocate research money, computerized eco-
nomic modeling should be first used to determine
whether a pharmacoeconomic study can be expected to
have a significant finding and thus be undertaken. ARDS
patients receiving a neuromuscular blocker have a high
mortality, and unpredictable outcome, which results in
large variability in costs per case. If a patient dies, there is
Recovery from 
block
Median time to 
recover from 
paralysis was 3.5 
hrs (1.82–5.18) in 
infusion group vs. 
6.3 hrs (3.40–9.19) 
in intermittent 
bolus group (p 
=.10)
Corticosteroids 
associated with 
more muscle 
weakness 20 of 69 
versus 0 of 38 (p < 
0.001)
Neuro- muscular 
Outcome
5 in the infusion 
group and 1 
intermittent had 
persistent severe 
muscle weakness
3 from each group 
had prolonged 
recovery >12 hrs.
None of the 
patients had 
muscle weakness
20 weak patients 
were paralysed 
longer 3.4 +/- 2.4 
versus 0.6 +/- 0.7 
d (p < 0.001)
18 of 20 weak pts 
paralysed > 24 h.
19 had motor & 
sensory findingss
no relationship 
between 
neurophys. 
abnormality & 
APACHE II score, 
organ failure, 
sepsis, muscle 
relaxant, or 
steroids
Mortality 23%
DOX shorter 
recovery time 
after >2 days of 
administration. 
(279.8 vs. 138.8 
mins)
no cases of 
prolonged 
neuromuscular 
block
10/23 had EMG, 9 
of 10 had 
axonopathy, 8 
were 
sensorimotor
Mortality 21%
Table 7: ICU studies of mechanically ventilated patients receiving neuromuscular blockers (Continued)BMC Medical Informatics and Decision Making 2006, 6:15 http://www.biomedcentral.com/1472-6947/6/15
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no benefit to any drug or intervention that reduces venti-
lation time or AQMS incidence. Consequently, a prospec-
tive, randomized pharmacoeconomic study of
neuromuscular blockers in the ICU to assess AQMS or
intubation times is impractical.
Published studies comparing neuromuscular blockers in
the ICU for ARDS are limited by the heterogeneity of
study methods and outcomes (e.g., each study defined
myopathy/weakness differently). We found that the best
way to increase net monetary benefit would be for the
drug to affect the key variable – the chance of a patient
dying. The benefit in spending extra money on such a
drug is more likely to be important in a subset of critically
ill patients identified as having prolonged intubation and
a low chance of death.
Neuromuscular blockers and recovery
The optimal balance between sedation and paralysis in
ARDS patients is unclear. Since the probability of having
a positive net monetary benefit is only for 51% of
patients, practitioners choosing neuromuscular blockers
need to consider risk factors for a patient developing
AQMS such as female gender, the number of days with
dysfunction of two or more organs, duration of mechani-
cal ventilation, and administration of corticosteroids. It
may be that the recognition of the problem of AQMS and
consequent avoidance of or decrease in dosing of neu-
The results of computer modeling Figure 2
The results of computer modeling. The x- axis has the mean incremental QALYs and the y-axis has the mean incremental 
costs for the 10,000 Monte-Carlo simulations, each represented by a dot.
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romuscular blockers, particularly when corticosteroids are
given concurrently, in the ICU has reduced the incidence
of AQMS [19].
Assessing validity of computer modeling
The challenge is to design a useful model. Had we chosen
to evaluate just the portion of care that occurs in the ICU,
there would be less clinical uncertainty, because we would
neglect what happened to the patient after ICU discharge.
On the other hand, by including a six-month time frame,
there is increasing uncertainty related to the complex
course of the ARDS.
We tested the robustness of our modeling by comparing
what our computer simulation predicted with published
studies documenting the natural clinical progression of
ARDS patients. For example, our model predicted that
28% of patients (base case being a 55 year- with pneumo-
nia ARDS receiving neuromuscular blockade for 3.5 days)
would be discharged home after 6 months, and that 18%
would receive care in a long-term care facility. Both end-
points are consistent with a previous study of discharge
disposition [20]. Our model also predicts that patients
would have 15 ventilator free days, which matches well
with published studies [21]. Thus, the scattergram
obtained in Figure 2 reflects the uncertainties about how
the probabilities will change if a new drug is used to
reduce delays in neuromuscular recovery.
Costing issues
Each facility may be able to negotiate individual contracts
for neuromuscular blockers so the cost differences we esti-
mated based on average wholesale price may not apply to
a particular ICU.
Prolonged recovery from neuromuscular blockade may
add costs due to additional sedative drugs, mechanical
ventilation, and physician and nurse, ICU time. Impor-
tantly, the majority of the costs of treating patients with
ARDS are spent on those who eventually die [22]. A
detailed costing study of 193 critically ill adults found that
factors such as severity of illness, gender, age, mechanical
ventilation, emergency admission, and mortality were
only able to explain 34% of the variation in average daily
costs [23].
It may be that a good way to reduce time on mechanical
ventilation is to have a full time intensivist rounding in
the ICU 10–12 hours a day repeatedly evaluating the
patient for extubation. However, in many ICUs this may
not be available. A six-hour reduction in time on the ven-
tilator may not be applicable in such settings. Although
from society's perspective six-hours of ventilator time is
important and measurable, from the hospital's perspec-
tive most of the cost of ICU care is a fixed cost. Even if a
patient spends three hours less in the ICU, institutional
costs may not be affected significantly because of the high
overhead costs of hospital care. Different ICUs will have a
different proportion of variable costs. In fact, nursing
labor productivity is most sensitive to the number of
admissions to the ICU each year and the method of com-
pensating nurses (e.g., salary or hourly).
Conclusion
The multifactorial etiology of AQMS, the highly variable
clinical course of patients with ARDS as well as the dis-
ease's high mortality rate, makes the determination of
whether selection of certain neuromuscular blockers
decreases the incidence of AQMS or reduces intubation
time difficult to answer. Our simulation computer model
predicted the mean cost for ARDS patients receiving
standard care for 6 months to be $62,238, with an overall
6-month mortality of 39%. Although it would be impor-
tant to determine if a particular neuromuscular blocker
diminishes the incidence of AQMS, a prospective, rand-
omized pharmacoeconomic study of neuromuscular
blockers in the ICU is impractical because of the highly
variable clinical course of patients with ARDS.
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